In a filing, Tscan Therapeutics Inc revealed its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $0.29 million on Dec 13 ’24. In the deal valued at $2.90 per share,100,000 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 5,357,347 shares worth roughly $9.32 million.
Then, Lynx1 Capital Management LP bought 31,800 shares, generating $95,629 in total proceeds. Upon buying the shares at $3.01, the 10% Owner now owns 5,257,347 shares.
Before that, Lynx1 Capital Management LP bought 947 shares. Tscan Therapeutics Inc shares valued at $4,114 were divested by the 10% Owner at a price of $4.34 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 5,225,547 shares, worth roughly $9.09 million.
BTIG Research initiated its Tscan Therapeutics Inc [TCRX] rating to a Buy in a research note published on May 16, 2024; the price target was $12. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Wedbush began covering TCRX with “an Outperform” recommendation on June 22, 2023.
Price Performance Review of TCRX
On Friday, Tscan Therapeutics Inc [NASDAQ:TCRX] saw its stock fall -2.79% to $1.74. Over the last five days, the stock has lost -12.12%. Tscan Therapeutics Inc shares have fallen nearly -42.76% since the year began. Nevertheless, the stocks have fallen -74.26% over the past one year. While a 52-week high of $9.69 was reached on 01/03/25, a 52-week low of $1.71 was recorded on 03/11/25. SMA at 50 days reached $2.3202, while 200 days put it at $4.8422.
Levels Of Support And Resistance For TCRX Stock
The 24-hour chart illustrates a support level at 1.6833, which if violated will result in even more drops to 1.6267. On the upside, there is a resistance level at 1.8433. A further resistance level may holdings at 1.9467. The Relative Strength Index (RSI) on the 14-day chart is 34.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1476, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.81%. Stochastics %K at 11.82% indicates the stock is a buying.
How much short interest is there in Tscan Therapeutics Inc?
A steep rise in short interest was recorded in Tscan Therapeutics Inc stocks on 2025-02-28, growing by 0.41 million shares to a total of 2.23 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 1.82 million shares. There was a rise of 18.26%, which implies that there is a positive sentiment for the stock.
